Drug Profile
PR 104
Alternative Names: PR-104; SN-29244Latest Information Update: 22 Sep 2015
Price :
$50
*
At a glance
- Originator Proacta Therapeutics
- Developer Proacta; Proacta Therapeutics
- Class Antineoplastics; Benzamides; Nitrogen mustard compounds; Small molecules
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Solid tumours
- Discontinued Liver cancer; Non-small cell lung cancer; Small cell lung cancer
Most Recent Events
- 22 Sep 2015 No recent reports on development identified - Phase-I for Solid tumours in New Zealand (IV)
- 22 Sep 2015 No recent reports on development identified - Phase-I/II for Acute myeloid leukaemia in USA (IV)
- 15 Nov 2011 Adverse events data from a phase I trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)